| Withdrawal of pioglitazone in patients with type 2 diabetes mellitus. | |
| | |
MedLine Citation:
|
PMID: 20831543 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND AND OBJECTIVE: The remodelling of the adipose tissue by pioglitazone may be associated with the sustained therapeutic effects. We studied the effects of withdrawal of pioglitazone after 3-month treatment on glucose, lipid and high-molecular weight (HMW) adiponectin levels as well as liver function in patients with type 2 diabetes mellitus. METHODS: Forty-nine Japanese patients with type 2 diabetes mellitus were randomly assigned into the withdrawal group after 3-month treatment with pioglitazone (15 or 30 mg daily) and the non-withdrawal group. RESULTS AND DISCUSSION: Three-month treatment with pioglitazone improved glycaemic control, homeostasis model assessment for insulin resistance (HOMA), dyslipidaemia and liver function tests in association with a marked increase in serum HMW adiponectin level. Three months later after the withdrawal of pioglitazone, however, fasting plasma glucose and HOMA increased, whereas serum HMW adiponectin decreased to the pretreatment levels. Dyslipidaemia also returned to the pretreatment level. On the other hand, liver enzymes at 3 months after the withdrawal remained lower after a mild rebound. In addition, the bone formation marker, serum bone-specific alkaline phosphatase, was significantly reduced by pioglitazone treatment in post-menopausal women. CONCLUSIONS: The present study suggests that 3-month treatment with pioglitazone has no sustained beneficial effects except in liver function tests in patients with type 2 diabetes mellitus. |
| | |
Authors:
|
M Iwase; T Asano; N Sasaki; H Yoshizumi; S Hiramatsu; Y Sakai; A Ogo; M Iida |
Related Documents
:
|
17214393 - Two-year effect of rosiglitazone in chinese poorly controlled type 2 diabetic patients. 6345193 - Effect of metformin on blood glucose, insulin and c-peptide responses to glucagon in no... 17016953 - Multiple-micronutrient fortification technology development and evaluation: from lab to... |
Publication Detail:
|
Type: Journal Article; Randomized Controlled Trial |
Journal Detail:
|
Title: Journal of clinical pharmacy and therapeutics Volume: 35 ISSN: 1365-2710 ISO Abbreviation: J Clin Pharm Ther Publication Date: 2010 Aug |
Date Detail:
|
Created Date: 2010-09-13 Completed Date: 2010-12-27 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8704308 Medline TA: J Clin Pharm Ther Country: England |
Other Details:
|
Languages: eng Pagination: 401-8 Citation Subset: IM |
Affiliation:
|
Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, Higashi-ku, Fukuoka, Japan. iwase@intmed2.med.kyushu-u.ac.jp |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adiponectin
/
blood Alkaline Phosphatase / blood Blood Glucose / drug effects Diabetes Mellitus, Type 2 / blood, drug therapy* Drug Administration Schedule Dyslipidemias / metabolism Female Humans Hypoglycemic Agents / administration & dosage*, therapeutic use Insulin Resistance Japan Liver Function Tests Male Middle Aged Postmenopause Thiazolidinediones / administration & dosage*, therapeutic use |
| Chemical | |
Reg. No./Substance:
|
0/Adiponectin; 0/Blood Glucose; 0/Hypoglycemic Agents; 0/Thiazolidinediones; 111025-46-8/pioglitazone; EC 3.1.3.1/Alkaline Phosphatase |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Chronic dialysis-associated anaemia in end-stage renal disease: analysis of management in two French...
Next Document: Marketing of rural and remote pharmacy practice via the digital medium.